1Formation and Purpose Sample Clauses
1Formation and Purpose. No later than two (2) years prior to the anticipated First Commercial Sale of a Licensed Product in the Profit-Sharing Territory, the Parties shall establish and convene a joint commercialization committee (the “JCC”). The JCC shall consist of an equal number of representatives from each Party and operate by the procedures in accordance with this Section 2.2. The purpose of the JCC shall be to provide a forum for the discussion and information exchange regarding Licensee’s Commercialization activities for the Licensed Products in the Profit-Sharing Territory and Major European Markets.
1Formation and Purpose. The Parties shall establish and convene a joint development committee (the “JDC”) within [***] after the Effective Date. The JDC shall consist of an equal number of representatives from each Party and operate by the procedures in accordance with this Section 2.1. The purpose of the JDC shall be to provide a forum for the coordination, communication and oversight of the Parties’ Development activities for the Licensed Compounds and Licensed Products under this Agreement, including the resolution of disputes properly referred to the JDC under this Agreement.
1Formation and Purpose. Genmab and SGI have established a joint chemistry, manufacturing & controls committee pursuant to the Collaboration Agreement and wish to clarify and modify its role by way of forming a “Joint Chemistry, Manufacturing & Controls Team” or “JCMCT” hereunder solely for the purposes of activities related to the Product to be conducted under this Agreement as set forth herein. The JCMCT shall consist of [*] representatives from each Party (or such other equal number of representatives from each Party as may be agreed by mutual Party Written Consent). Subject to the oversight of the JSC and Sections 2.1 and 2.10, the JCMCT shall oversee the Manufacture and supply of the Product globally, as well as all CMC Development activities and the global supply chain. The JCMCT shall operate by the procedures set forth in Section 2.10. For the avoidance of doubt, the specific allocation of responsibilities for Manufacturing activities between Genmab and SGI shall be made in [*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that we treat as private or confidential. accordance with ARTICLE 6 and as of the Effective Date the joint chemistry, manufacturing & controls committee formed under the Collaboration Agreement shall be superseded and replaced by the JCMCT and shall disband and have no further role, rights, or responsibilities with respect to the Product.
1Formation and Purpose. Simultaneously with the formation of the JCC, the Parties shall establish and convene a joint finance committee (the “JFC”). The JFC shall consist of an equal number of representatives from each Party and operate by the procedures in accordance with this Section 2.3. The purpose of the JFC shall be to provide a forum for the discussion and information exchange relating to financial matters.
1Formation and Purpose. Genmab and SGI have established a “Joint Development Team” or “JDT” pursuant to the Collaboration Agreement and wish to clarify and modify its role by way of forming a “Joint Development Committee” or “JDC” hereunder for the purposes of activities related to the Product to be conducted under this Agreement as set forth herein and to assume the role of the JDT under the Collaboration Agreement solely with respect to the Product (and for clarity the JDT shall continue to have the roles and responsibilities as set forth under the Collaboration Agreement with respect to Licensed Products (defined thereunder) that are not the Product). The JDC shall consist of [*] representatives from each Party (or such other equal number of representatives from each Party as may be agreed by mutual Party Written Consent). Subject to the oversight of the JSC and subject to Sections 2.1 and 2.10, the JDC shall be principally responsible for overseeing the Development (other than CMC Development, which shall be subject to the oversight of the JCMCT) of the Product globally under the Collaboration Agreement and this Agreement, including coordination and implementation of activities between the Parties. The JDC shall operate by the procedures set forth in Section 2.10. For clarity, (a) the JDT formed under the Collaboration Agreement shall have no authority or other role with respect to the Product following the Effective Date, and (b) following the Effective Date, references in the Collaboration Agreement to the “Joint Development Team” or “JDT” solely as they relate to the Product shall refer to the JDC under this Agreement.
1Formation and Purpose. Genmab and SGI hereby agree to establish a joint medical affairs team solely for the purposes of activities related to the Product to be conducted under this Agreement as set forth herein (the “Joint Medical Affairs Team” or “JMAT”) within [*] days after the Effective Date. The JMAT shall constitute a Working Group of the JDC and shall consist of [*] representatives from each Party (or such other equal number of representatives from each Party as may be agreed by mutual Party Written Consent). The JMAT shall report to the JDC; provided, however, that notwithstanding anything contained herein to the contrary, the Combined Major Market Medical Affairs Plan prepared by the JMAT and its corresponding budget, and any amendments thereto which shall be proposed by the JMAT, shall be submitted directly to the JSC for its review and approval pursuant to Section 2.2.2. Subject to the oversight of the JDC, Sections 2.1 and 2.10, and ARTICLE 7, the JMAT shall be responsible for strategic oversight of the Medical Affairs Activities in the Major Markets with respect to the Product under this Agreement, including coordination of such activities between the Parties. The JMAT shall operate by the procedures set forth in Section 2.10. For the avoidance of doubt, the specific allocation of responsibilities for Medical Affairs Activities between Genmab and SGI shall be made in accordance with ARTICLE 7.